Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study

HIGHLIGHTS

• What: The study showed that tixagevimab/cilgavimab 150/150 mg is effective and safe in preventing infection and severe disease when administered to patients with weak or no response to COVID-19 vaccine. Although this study showed similar results as in the study , it was conducted when the B.1.1.529, BA.2, and BA.2.12.1 Omicron lineages were most prevalent in Massachusetts and the results cannot be generalized to BA.4 and BA.5. The authors compared for the first time, to the best of the knowledge , the occurrence and severity of SARS . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.